Additionally, our group is developing anti-ROR1 CAR engineered expanded primary NK cells through CAR mRNA electroporation technology to target ROR1+ solid tumors with promising in vitro anti-tumor effects (195). The gene discussed is ROR1; the disease is neoplasm.